We’re incredibly excited to announce our expansion into the United States, thanks to our partnership with Intermountain Health. Together, we’re on a mission to revolutionize newborn care! 

Did you know that three out of every five newborns develop jaundice? If left untreated, severe jaundice can lead to serious complications such as brain damage or hearing loss. 

Our innovative study led by Dr. Timothy Bahr, is focused on changing how we screen for jaundice and will involve approximately 300 term babies and 100 pre-term babies across Intermountain Utah Valley Hospital, Intermountain McKay-Dee Hospital, and Intermountain Medical Center.  

These precious babies will undergo bilirubin measurements using our Picterus® Jaundice Pro technology, alongside traditional blood draws, including measurements both pre- and post-phototherapy. 

At Picterus, we aim to empower parents and families by providing them with the ability to screen for hyperbilirubinemia in the comfort of their own homes, eliminating the cost and the inconvenience associated with clinic visits and lab tests. This initiative has already been approved for both professional and home use in Europe, and we are now looking to expand into the US.

For this reason, we’re incredibly proud to partner with Intermountain Health on this important initiative and are eagerly anticipating the positive impact it will have on pediatric care.